What happened, in summary

Abigail was 38, running a law firm, raising 2 young children, and breastfeeding when she felt a lump in her left breast in January 2017. She first thought it was a clogged duct. In April 2017, she was diagnosed with strongly hormone-positive breast cancer and initially staged as Stage IIA after lumpectomy with 4 lymph nodes removed. The plan was 4 rounds of Adriamycin/Cytoxan, followed by 12 rounds of Taxol and radiation. After her first chemo session, unexpected tumor-marker blood work led to a bone scan and CT scan. On June 22, 2017, she was told the cancer was Stage IV. A 5 cm tumor was in her right femur, and she later described cancer throughout her bones, including her spine, humeri, and femurs. She had titanium rods placed in both femurs, finished Adriamycin/Cytoxan, saved Taxol for later, and had surgery to remove ovarian estrogen sources. After chemotherapy, she received Ibrance and letrozole for 2 years. When the cancer mutated in 2019, she switched to Piqray for a PIK3CA mutation. Later, Piqray was combined with Faslodex and Kisqali for 2.5 years. As of October 2022, Abigail was living with metastatic breast cancer, later liver involvement, ongoing genomic testing, and advocacy for clinical trials.